PMN: Blinded 6-month interim data show strong safety and early biomarker signals in Alzheimer's patients
The 6-month blinded interim analysis of a Phase 1b Alzheimer's trial showed no ARIA-E, a low total ARIA rate, and favorable safety across all genotypes. Both plasma pTau217 and CSF MTBR-tau243 biomarkers declined, suggesting early target engagement and potential disease modification. Topline 12-mon…